Clinical Trial Update: Bevacizumab vs Dacarbazine in Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing bevacizumab versus dacarbazine in metastatic unresectable malignant melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Avastin (bevacizumab)
• Dacarbazine (dacarbazine)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Metastatic Malignant Melanoma, Unresectable Malignant Melanoma | Phase 2 | Status: TERMINATED